Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease

Eugenio Barone, Antonella Tramutola, Francesca Triani, Silvio Calcagnini, Fabio Di Domenico, Cristian Ripoli, Silvana Gaetani, Claudio Grassi, D. Allan Butterfield, Tommaso Cassano, Marzia Perluigi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms underlying INI beneficial effects are still unclear. We show that INI improves insulin signaling activation in the hippocampus and cortex of adult and aged 3×Tg-AD mice by ameliorating BVR-A activation. These changes were associated with a reduction of nitrosative stress, Tau phosphorylation, and Aβ oligomers in brain, along with improved cognitive functions. The role of BVR-A was strengthened by showing that cells lacking BVR-A: (i) develop insulin resistance if treated with insulin and (ii) can be recovered from insulin resistance only if treated with a BVR-A-mimetic peptide. These novel findings shed light on the mechanisms underlying INI treatment effects and suggest BVR-A as potential therapeutic target to prevent brain insulin resistance in AD.

Original languageEnglish
JournalMolecular Neurobiology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

biliverdin reductase
Alzheimer Disease
Insulin Resistance
Insulin
Brain
Intranasal Administration
Cognition
Hippocampus
Phosphorylation

Keywords

  • Alzheimer disease
  • Biliverdin reductase-A
  • Insulin resistance
  • Intranasal
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Barone, E., Tramutola, A., Triani, F., Calcagnini, S., Di Domenico, F., Ripoli, C., ... Perluigi, M. (Accepted/In press). Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1231-5

Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. / Barone, Eugenio; Tramutola, Antonella; Triani, Francesca; Calcagnini, Silvio; Di Domenico, Fabio; Ripoli, Cristian; Gaetani, Silvana; Grassi, Claudio; Butterfield, D. Allan; Cassano, Tommaso; Perluigi, Marzia.

In: Molecular Neurobiology, 01.01.2018.

Research output: Contribution to journalArticle

Barone, E, Tramutola, A, Triani, F, Calcagnini, S, Di Domenico, F, Ripoli, C, Gaetani, S, Grassi, C, Butterfield, DA, Cassano, T & Perluigi, M 2018, 'Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease', Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1231-5
Barone, Eugenio ; Tramutola, Antonella ; Triani, Francesca ; Calcagnini, Silvio ; Di Domenico, Fabio ; Ripoli, Cristian ; Gaetani, Silvana ; Grassi, Claudio ; Butterfield, D. Allan ; Cassano, Tommaso ; Perluigi, Marzia. / Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. In: Molecular Neurobiology. 2018.
@article{63a3e705ade843feb35ca727c6055f89,
title = "Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease",
abstract = "Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms underlying INI beneficial effects are still unclear. We show that INI improves insulin signaling activation in the hippocampus and cortex of adult and aged 3×Tg-AD mice by ameliorating BVR-A activation. These changes were associated with a reduction of nitrosative stress, Tau phosphorylation, and Aβ oligomers in brain, along with improved cognitive functions. The role of BVR-A was strengthened by showing that cells lacking BVR-A: (i) develop insulin resistance if treated with insulin and (ii) can be recovered from insulin resistance only if treated with a BVR-A-mimetic peptide. These novel findings shed light on the mechanisms underlying INI treatment effects and suggest BVR-A as potential therapeutic target to prevent brain insulin resistance in AD.",
keywords = "Alzheimer disease, Biliverdin reductase-A, Insulin resistance, Intranasal, Neuroprotection",
author = "Eugenio Barone and Antonella Tramutola and Francesca Triani and Silvio Calcagnini and {Di Domenico}, Fabio and Cristian Ripoli and Silvana Gaetani and Claudio Grassi and Butterfield, {D. Allan} and Tommaso Cassano and Marzia Perluigi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12035-018-1231-5",
language = "English",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease

AU - Barone, Eugenio

AU - Tramutola, Antonella

AU - Triani, Francesca

AU - Calcagnini, Silvio

AU - Di Domenico, Fabio

AU - Ripoli, Cristian

AU - Gaetani, Silvana

AU - Grassi, Claudio

AU - Butterfield, D. Allan

AU - Cassano, Tommaso

AU - Perluigi, Marzia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms underlying INI beneficial effects are still unclear. We show that INI improves insulin signaling activation in the hippocampus and cortex of adult and aged 3×Tg-AD mice by ameliorating BVR-A activation. These changes were associated with a reduction of nitrosative stress, Tau phosphorylation, and Aβ oligomers in brain, along with improved cognitive functions. The role of BVR-A was strengthened by showing that cells lacking BVR-A: (i) develop insulin resistance if treated with insulin and (ii) can be recovered from insulin resistance only if treated with a BVR-A-mimetic peptide. These novel findings shed light on the mechanisms underlying INI treatment effects and suggest BVR-A as potential therapeutic target to prevent brain insulin resistance in AD.

AB - Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms underlying INI beneficial effects are still unclear. We show that INI improves insulin signaling activation in the hippocampus and cortex of adult and aged 3×Tg-AD mice by ameliorating BVR-A activation. These changes were associated with a reduction of nitrosative stress, Tau phosphorylation, and Aβ oligomers in brain, along with improved cognitive functions. The role of BVR-A was strengthened by showing that cells lacking BVR-A: (i) develop insulin resistance if treated with insulin and (ii) can be recovered from insulin resistance only if treated with a BVR-A-mimetic peptide. These novel findings shed light on the mechanisms underlying INI treatment effects and suggest BVR-A as potential therapeutic target to prevent brain insulin resistance in AD.

KW - Alzheimer disease

KW - Biliverdin reductase-A

KW - Insulin resistance

KW - Intranasal

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=85051645596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051645596&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1231-5

DO - 10.1007/s12035-018-1231-5

M3 - Article

AN - SCOPUS:85051645596

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -